153 related articles for article (PubMed ID: 36063280)
1. Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm.
O'Haire S; Degeling K; Franchini F; Tran B; Luen SJ; Gaff C; Smith K; Fox S; Desai J; IJzerman M
Target Oncol; 2022 Sep; 17(5):539-548. PubMed ID: 36063280
[TBL] [Abstract][Full Text] [Related]
2. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer.
Wallenta Law J; Bapat B; Sweetnam C; Mohammed H; McBratney A; Izano MA; Scannell Bryan M; Spencer S; Schroeder B; Hostin D; Simon GR; Berry AB
JCO Precis Oncol; 2024 May; 8():e2400075. PubMed ID: 38754057
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of psychological distress and associated factors among patients undergoing comprehensive genomic profiling testing: protocol for a multicentre, prospective, observational study.
Matsuoka A; Fujimori M; Koyama T; Sato A; Mori K; Hirata M; Tanabe N; Nakachi K; Kato S; Okamoto H; Ogawa K; Komatsu H; Iwasaku M; Miyaji T; Uchitomi Y
BMJ Open; 2023 Nov; 13(11):e072472. PubMed ID: 37996226
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis.
Sivakumar S; Lee JK; Moore JA; Hopkins J; Newberg JY; Madison R; Graf R; Schrock AB; Kobetz E; Vince R; Franco I; Seldon C; Frampton GM; Mills J; Venstrom J; Mahal BA
Lancet Digit Health; 2023 Jun; 5(6):e380-e389. PubMed ID: 37236698
[TBL] [Abstract][Full Text] [Related]
5. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
[TBL] [Abstract][Full Text] [Related]
6. Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling.
Binder C; Matthes KL; Korol D; Rohrmann S; Moch H
Cancer Med; 2018 Sep; 7(9):4814-4824. PubMed ID: 30019510
[TBL] [Abstract][Full Text] [Related]
7. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
[TBL] [Abstract][Full Text] [Related]
8. Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.
Tomlins SA; Hovelson DH; Suga JM; Anderson DM; Koh HA; Dees EC; McNulty B; Burkard ME; Guarino M; Khatri J; Safa MM; Matrana MR; Yang ES; Menter AR; Parsons BM; Slim JN; Thompson MA; Hwang L; Edenfield WJ; Nair S; Onitilo A; Siegel R; Miller A; Wassenaar T; Irvin WJ; Schulz W; Padmanabhan A; Harish V; Gonzalez A; Mansoor AH; Kellum A; Harms P; Drewery S; Falkner J; Fischer A; Hipp J; Kwiatkowski K; Lazo de la Vega L; Mitchell K; Reeder T; Siddiqui J; Vakil H; Johnson DB; Rhodes DR
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34476329
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
Madison R; Schrock AB; Castellanos E; Gregg JP; Snider J; Ali SM; Miller VA; Singal G; Alexander BM; Venstrom JM; Chung JH
Lung Cancer; 2020 Oct; 148():69-78. PubMed ID: 32823229
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice.
Fukada I; Mori S; Hayashi N; Hosonaga M; Xiaofei W; Yamazaki M; Ueki A; Kiyotani K; Tonooka A; Takeuchi K; Ueno T; Takahashi S
Cancer Sci; 2023 Dec; 114(12):4632-4642. PubMed ID: 37858313
[TBL] [Abstract][Full Text] [Related]
11. The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology.
Kubo T; Sunami K; Koyama T; Kitami M; Fujiwara Y; Kondo S; Yonemori K; Noguchi E; Morizane C; Goto Y; Maejima A; Iwasa S; Hamaguchi T; Kawai A; Namikawa K; Arakawa A; Sugiyama M; Ohno M; Yoshida T; Hiraoka N; Yoshida A; Yoshida M; Nishino T; Furukawa E; Narushima D; Nagai M; Kato M; Ichikawa H; Fujiwara Y; Kohno T; Yamamoto N
ESMO Open; 2024 Apr; 9(4):102981. PubMed ID: 38613908
[TBL] [Abstract][Full Text] [Related]
12. Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study.
Best MC; Bartley N; Napier CE; Fisher A; Ballinger ML; Thomas DM; Goldstein D; Tucker K; Biesecker BB; Butow P
Support Care Cancer; 2022 Oct; 30(10):8201-8210. PubMed ID: 35809119
[TBL] [Abstract][Full Text] [Related]
13. Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: A prospective multicenter study.
Takada K; Kubo T; Kikuchi J; Yoshida M; Murota A; Arihara Y; Nakamura H; Nagashima H; Tanabe H; Sugita S; Tanaka Y; Miura A; Ohhara Y; Ishiguro A; Yokouchi H; Kawamoto Y; Mizukami Y; Ohnishi H; Kinoshita I; Sakurai A
Front Oncol; 2022; 12():988527. PubMed ID: 36119486
[TBL] [Abstract][Full Text] [Related]
14. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
[TBL] [Abstract][Full Text] [Related]
16. An approach for improvement of the accuracy of cancer gene panel testing.
Imoto K; Yamamoto H; Ohkawa C; Shimada N; Ikuzawa R; Takeda H; Ohhara T; Kojima Y; Furuya N; Motoyoshi A; Migita O; Kuga A; Keira T; Wakamatsu H; Sato T; Oike N; Koike J; Yamano Y; Sunakawa Y
Int J Clin Oncol; 2024 May; 29(5):571-581. PubMed ID: 38472663
[TBL] [Abstract][Full Text] [Related]
17. [Questionnaire Survey on the Timing of Comprehensive Genomic Profiling for Advanced Recurrent Colorectal Cancer and Its Impact on Patients].
Yarimizu A; Kuribayashi M; Nomura K; Kimura K; Takenaka Y; Song J; Ohashi E; Nishimura Y; Demachi T; Hirata M; Beppu N; Uchino M; Ikeuchi H; Ikeda M; Kataoka K
Gan To Kagaku Ryoho; 2023 Aug; 50(8):891-893. PubMed ID: 37608415
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy.
Hilal T; Nakazawa M; Hodskins J; Villano JL; Mathew A; Goel G; Wagner L; Arnold SM; DeSimone P; Anthony LB; Hosein PJ
BMC Cancer; 2017 Aug; 17(1):602. PubMed ID: 28854908
[TBL] [Abstract][Full Text] [Related]
19. Clinical Benefit of Comprehensive Genomic Profiling for Advanced Cancers in India.
Mathew A; Joseph S; Boby J; Benny S; Veedu J; Rajappa S; Rohatgi N; Sirohi B; Jain R; Agarwala V; Shukla DK; Mehta A; Pramanik R; Talwar V; Maka V; Raut N
JCO Glob Oncol; 2022 Mar; 8():e2100421. PubMed ID: 35404667
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
